Goethe University Frankfurt at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Goethe University Frankfurt brings 4 presentations to ESGCT 2026 in Hamburg. Its contributions cover engineered CAR NK cells for blood cancers alongside the clinical and regulatory side of gene therapy. The cell work targets CLEC12A, CD33 and BCMA to counter antigen loss, while other work addresses haemophilia treatment and artificial intelligence in advanced therapy regulation.
| Organization | ESGCT 2026 Attendance |
|---|---|
Goethe University Frankfurt Frankfurt, Germany | |
Public research university in Frankfurt am Main, Germany. | Poster Thu Oct 29 2:00pm–4:00pm From llama towards immunotherapy: Development of VHH-based dual CAR-NK cells targeting CLEC12A and CD33 to improve safety and efficacy in AML treatment Poster Thu Oct 29 2:00pm–4:00pm Genome-wide CRISPR screen-guided engineering of tailored BCMA-CAR NK cells to overcome antigen loss in multiple myeloma Talk Fri Oct 30 9:00am–10:30am Current status of gene therapy for haemophilia Rare and inherited diseaseClinical trials and translation Talk Fri Oct 30 11:00am–1:00pm AI in ATMP regulations Manufacturing, CMC and access Chair Fri Oct 30 11:00am–1:00pm SESSION 12c: Regulatory & Ethics Manufacturing, CMC and access |
Instantly find 20 buyers from Goethe University Frankfurt
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction